Los Angeles, USA, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Migraine Pipeline Space Brims with Novel Emerging Therapies with Over 30 Pharma Players Working in the Domain |DelveInsight
The Migraine Pipeline landscape is robust and fueled with new therapies which hold the promise to change the migraine treatment regimen in coming years.
DelveInsight's 'Migraine Pipeline Insights' report offers comprehensive coverage of the emerging Migraine therapies in different stages of clinical trials from pre-clinical till a late-end stage, along with dormant, inactive and abandoned drugs agents.
The Migraine Pipeline report offers a complete view of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space and opportunities along with the hurdles across the Migraine Pipeline domain.
Some of the key highlights from the Migraine Pipeline report:
- The Migraine Pipeline report offers a rich analysis of 30+ key players and 30+ key therapies.
- Migraine pipeline comprises therapies in different stages of the clinical phase such as include Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, AbbVie, Eli Lilly and Company, Allodynic Therapeutics, Trevena, AEON Biopharma, Sosei Heptares, Vaxxinity, Pulmatrix, Pear Therapeutics, BetterLife Pharma, and others, with many others expected to enter the Migraine market in the coming next decade.
- Some of the key companies engaged in strengthening the Migraine Pipeline are Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics, among others.
- In June 2021, Sosei Group Corporation announced the initiation of Phase I clinical study of HTL0022562 (also known as BHV3100), a novel, small-molecule CGRP receptor antagonist, for the treatment of migraine. (NCT04941989)
- In March 2021, AbbVie announced that the US FDA accepted a new drug application (NDA) for atogepant for the preventive treatment of Migraines. The NDA approval was supported by data from a pivotal Phase III ADVANCE clinical trial, a pivotal Phase IIb/III study, and a Phase III long-term safety study.
- In March 2021, Biohaven Pharmaceutical enrolled the first subject in Phase II/III clinical trial of oral zavegepant for the preventive treatment of migraine (NCT04804033).
Request for Sample to know more about the emerging therapy anticipated to grab maximum patient pool @ Migraine Emerging Therapies and Forecast
Migraine is a medical condition that causes severe, recurring headaches and other symptoms such as tingling sensations, flashing lights, weird sounds, and blurred or lost vision. The condition has no cure; however, treatments are available, including pain relief over-the-counter (OTC) drugs.
For more information on emerging drugs, visit Migraine Pipeline Analysis
Migraine Pipeline Drugs
| Drug | Company | Phase | MoA | RoA |
| Zavegepant | Biohaven Pharmaceuticals | Phase III | Calcitonin gene-related peptide receptor antagonists | Oral/Intranasal |
| STS-101 | Satsuma Pharmaceuticals | Phase III | Serotonin 1B receptor agonists | Intranasal |
| Atogepant | AbbVie | Preregistration | Calcitonin gene-related peptide antagonists | Oral |
| LY-3451838 | Eli Lilly and Company | Phase II | Pituitary adenylate cyclase-activating polypeptide receptor antagonists | Intravenous |
| ALLOD 2 | Allodynic Therapeutics | Phase II/III | Cyclo-oxygenase 2 inhibitors | Oral |
| TRV-250 | Trevena | Phase II | Opioid delta receptor agonists | Subcutaneous |
| Prabotulinumtoxin A | AEON Biopharma | Phase II | Acetylcholine inhibitors | Intramuscular |
| HTL 0022562 | Sosei Heptares | Phase I | Calcitonin gene-related peptide antagonists | Subcutaneous |
| UB 313 | Vaxxinity | Preclinical | Calcitonin gene-related peptide receptor antagonists | NA |
Request for Sample to know more @ Migraine Pipeline Analysis, Key Companies, and Futuristic Trends
Migraine Therapeutic Assessment
The Migraine Pipeline report lays down complete insights into active Migraine emerging therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
By Product Type
- Mono
- Combination
By Stage
- Discovery
- Pre-clinical
- IND
- Phase I
- Phase II
- Phase III
- Pre-registration
By Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
By Route of Administration
- Intramuscular
- Intranasal
- Oral
- Subcutaneous
- Intravenous
By Mechanism of Action
- Calcitonin gene-related peptide receptor antagonists
- Serotonin 1B receptor agonists
- Pituitary adenylate cyclase-activating polypeptide receptor antagonists
- Cyclo-oxygenase 2 inhibitors
- Opioid delta receptor agonists
- Acetylcholine inhibitors
By Targets
- Calcitonin gene-related peptide receptor
- Serotonin 1B receptor
- Pituitary adenylate cyclase-activating polypeptide receptor
- Cyclo-oxygenase 2
- Opioid delta receptor
- Acetylcholine
Get in touch with our Business executive for Informative Business Decisions, In/Out-Licensing Services, Drug Portfolio Management and Consulting Solutions
Scope of the Migraine Pipeline Report
Coverage: Global
Key Players: Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, AbbVie, Eli Lilly and Company, Allodynic Therapeutics, Trevena, AEON Biopharma, Sosei Heptares, Vaxxinity, Pulmatrix, Pear Therapeutics, BetterLife Pharma, and others.
Key Migraine Pipeline Therapies: Zavegepant, STS-101, Atogepant, LY-3451838, ALLOD 2, TRV-250, Prabotulinumtoxin A, HTL 0022562, UB 313, PUR-3100, TD 0148A, and others.
Reach out @ Migraine Pipeline: Novel therapies and Emerging technologies
Table of Contents
| 1 | Report Introduction |
| 2 | Migraine Disease Overview |
| 3 | Migraine Pipeline Outlook |
| 4 | Comparative Analysis |
| 5 | Migraine Therapeutic Products in Clinical Stage |
| 6 | Migraine Late Stage Products (Phase III) |
| 7 | Migraine Mid Stage Products (Phase II) |
| 8 | Migraine Early Stage Products (Phase I) |
| 9 | Migraine Therapeutic Products in Non-clinical Stage |
| 10 | Migraine Preclinical and Discovery Stage Products |
| 11 | Migraine – DelveInsight’s Analytical Perspective |
| 12 | In-depth Commercial Assessment |
| 13 | Migraine Collaboration Deals |
| 14 | Migraine Therapeutics Pipeline Analysis |
| 15 | Inactive Migraine Pipeline Products |
| 16 | Migraine Key Companies |
| 17 | Migraine- Unmet Needs |
| 18 | Migraine Market Drivers and Barriers |
| 19 | Migraine- Future Perspectives and Conclusion |
| 20 | Appendix |
| 21 | Report Methodology |
| 22 | Consulting Services |
| 23 | Disclaimer |
| 24 | About DelveInsight |
Visit to know more of what's covered @ Migraine Emerging Therapies, Treatments and Ongoing Clinical Trials
Related Reports
Migraine Market
DelveInsight's 'Migraine – Market Insights, Epidemiology, and Market Forecast —2030' report.
Brain Hemorrhage Market
DelveInsight's "Brain Hemorrhage - Market Insights, Epidemiology, and Market Forecast-2030" report.
Charcot Marie Tooth Disease Market
DelveInsight's 'Charcot–Marie–Tooth Disease -Market Insights, Epidemiology, and Market Forecast –2030' report.
Chronic Pain Market
DelveInsight's 'Chronic Pain - Market Insights, Epidemiology, and Market Forecast—2030' report.
Chronic Traumatic Encephalopathy Market
DelveInsight's "Chronic Traumatic Encephalopathy (CTE) - Market Insights, Epidemiology, and Market Forecast-2030" report.
Cluster Headache Market
DelveInsight's 'Cluster Headache Market Insights, Epidemiology, and Market Forecast—2030' report
Browse through blog posts
Migraine Market
Neurological Disorders and Recent Breakthroughs in the Market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
